, Tracking Stock Market Picks
Enter Symbol:

up 29.13 %

ARDEA BIOSCIENCES (RDEA) rated Outperform by Boenning & Scattergood

Posted on: Tuesday,  May 31, 2011  10:25 AM ET by Boenning & Scattergood

Boenning & Scattergood rated Outperform ARDEA BIOSCIENCES (NASDAQ: RDEA) on 05/31/2011, when the stock price was $24.75. Since
then, ARDEA BIOSCIENCES has gained 29.13% as of 06/19/2012's recent price of $31.96.
If you would have followed this Boenning & Scattergood's recommendation on RDEA, you would have gained 29.13% of your investment in 385 days.

Ardea Biosciences, Inc. is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of human immunodeficiency virus (HIV), cancer and inflammatory diseases, including gout. The Company's portfolio of product candidates include RDEA806 and 2nd generation non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV indication; RDEA594 for gout; RDEA119 for cancer; RDEA119 for inflammation, and mitogen-activated ERK kinase (MEK) inhibitor for cancer/inflammation.

Our equity research team concentrates on companies that aren’t widely covered in sectors such as water distribution/equipment/technology, financial services, business services, aerospace & defense technology, medical technology and retail.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/31/2011 10:25 AM Buy
as of 12/30/2011
1 Week down  -3.99 %
1 Month down  -10.01 %
3 Months up  7.61 %
1 YTD down  -32.08 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy